Printer Friendly

Allos Therapeutics gets EU Orphan Medicinal Product designation for pralatrexate in Hodgkin lymphoma.

M2 PHARMA-October 15, 2010-Allos Therapeutics gets EU Orphan Medicinal Product designation for pralatrexate in Hodgkin lymphoma(C)2010 M2 COMMUNICATIONS

15 October 2010 - US Allos Therapeutics Inc (NASDAQ: ALTH) said today that the European Commission (EC) has granted Orphan Medicinal Product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL).

The company said it is currently investigating pralatrexate in a number of ongoing studies, including a Phase II clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

The EC previously granted orphan designations for pralatrexate for the treatment of patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and non-papillary transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer.

Under EC legislation, Orphan Medicinal Product designation provides ten years of potential market exclusivity once the product candidate is approved for marketing for the designated indication in the EU.

Orphan Medicinal Product designation also allows for protocol assistance free of charge on clinical trials, a reduced Marketing Authorisation Application (MAA) filing fee and the potential for grant funding.

This designation is based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), the company further said.

((Comments on this story may be sent to

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 15, 2010
Previous Article:GI Dynamics gets European CE Mark approval of EndoBarrier treatment of Type 2 diabetes, obesity.
Next Article:Genentech, Biogen Idec report Phase II study data for ocrelizumab in RRMS.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters